Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting


Exelixis Inc EXEL announced that the CONTACT-01 study did not meet its primary endpoint of overall survival at the final analysis. 

  • CONTACT-01 is a phase 3 trial evaluating Cabometyx (cabozantinib) in combination with Tecentriq (atezolizumab) versus docetaxel in metastatic non-small cell lung cancer (NSCLC) without actionable mutations who experienced disease progression on or after treatment.
  • Related: Exelixis Announces Detailed Results From Late-Stage Cabometyx Combo Trial In Kidney Cancer.
  • The safety profile of the combination of cabozantinib and atezolizumab observed in the trial was consistent with the known safety profiles for each single agent.
  • No new safety signals were identified. 
  • Secondary endpoints included progression-free survival, objective response rate, and duration of response. 
  • CONTACT-01 was sponsored by Roche Holdings AG RHHBY and co-funded by Exelixis. 
  • Ipsen IPSEY and Takeda Pharmaceutical Co Ltd TAK opted to participate in the trial and are contributing to this study's funding under the companies' terms and respective collaboration agreements with Exelixis. 
  • Price Action: EXEL shares are down 0.97% at $16.36 during the premarket session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!